(Q43194443)

English

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients

scientific article published in October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 November 2017

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients (English)

1 reference

Europe PubMed Central

15 November 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

M Benucci

1

1 reference

Europe PubMed Central

15 November 2017

F Li Gobbi

2

1 reference

Europe PubMed Central

15 November 2017

L Sabadini

3

1 reference

Europe PubMed Central

15 November 2017

G Saviola

4

1 reference

Europe PubMed Central

15 November 2017

P Baiardi

5

1 reference

Europe PubMed Central

15 November 2017

M Manfredi

6

1 reference

Europe PubMed Central

15 November 2017

publication date

1 October 2009

1 reference

Europe PubMed Central

15 November 2017

International Journal of Immunopathology and Pharmacology

1 reference

Europe PubMed Central

15 November 2017

22

1 reference

Europe PubMed Central

15 November 2017

4

1 reference

Europe PubMed Central

15 November 2017

1147-1152

1 reference

Europe PubMed Central

15 November 2017

Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Measurement of health state utilities for economic appraisal

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

https://api.crossref.org/works/10.1177%2F039463200902200434

21 January 2018

Identifiers

10.1177/039463200902200434

1 reference

Europe PubMed Central

15 November 2017

1 reference

Europe PubMed Central

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43194443&oldid=1983277090"